Molecular Assessment of Artemisinin Resistance Markers in Eastern and Western Border Areas of Myanmar

NCT ID: NCT02198573

Last Updated: 2014-07-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

91 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-07-31

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* Artemisinin resistance have been documented in Myanmar and Myanmar artemisinin resistance containment measures have been launched since 2009-2010.
* It is important to monitor the spread and magnitude of artemisinin resistant malaria in Myanmar.
* So, day-3 surveillance study have been conducted.
* Recently artemisinin resistant molecular marker, K13 have been identified and it was used as a tool in this study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Day-3 Positive of Parasitaemia Prevalence of Drug Resistance Gene Mutation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* confirmed uncomplicated falciparum malaria patients.
* age \>2 years
* box sex
* given informed consent

Exclusion Criteria

* severe malaria
* did not give informed consent
* others diseases
Minimum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kangwon National University

OTHER

Sponsor Role collaborator

Myat Htut Nyunt

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Myat Htut Nyunt

Dr. Myat Htut Nyunt

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Myat P Kyaw, PhD

Role: STUDY_DIRECTOR

Department of Medical Research, Lower Myanmar

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dr. Myat Phone Kyaw

Yangon, Yangon, Burma

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Burma

References

Explore related publications, articles, or registry entries linked to this study.

World Health Organization. World Malaria Report 2013. Geneva, Switzerland, 2013.

Reference Type BACKGROUND

World Health Organization. Global report on antimalarial efficacy and drug resistance: 2000-2010. Geneva, Switzerland: World Health Organization, 2010.

Reference Type BACKGROUND

Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, Binh TQ, D'Alessandro U, Day NP, de Vries PJ, Dorsey G, Guthmann JP, Mayxay M, Newton PN, Olliaro P, Osorio L, Price RN, Rowland M, Smithuis F, Taylor WR, Nosten F, White NJ. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis. 2010 Feb 15;201(4):570-9. doi: 10.1086/650301.

Reference Type BACKGROUND
PMID: 20085495 (View on PubMed)

Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Menard D. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014 Jan 2;505(7481):50-5. doi: 10.1038/nature12876. Epub 2013 Dec 18.

Reference Type BACKGROUND
PMID: 24352242 (View on PubMed)

Singh B, Bobogare A, Cox-Singh J, Snounou G, Abdullah MS, Rahman HA. A genus- and species-specific nested polymerase chain reaction malaria detection assay for epidemiologic studies. Am J Trop Med Hyg. 1999 Apr;60(4):687-92. doi: 10.4269/ajtmh.1999.60.687.

Reference Type BACKGROUND
PMID: 10348249 (View on PubMed)

Kyaw MP, Nyunt MH, Chit K, Aye MM, Aye KH, Aye MM, Lindegardh N, Tarning J, Imwong M, Jacob CG, Rasmussen C, Perin J, Ringwald P, Nyunt MM. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS One. 2013;8(3):e57689. doi: 10.1371/journal.pone.0057689. Epub 2013 Mar 8.

Reference Type RESULT
PMID: 23520478 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

WHO_3DF_2013_day3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Artemisinin Resistance in Cambodia
NCT00479206 COMPLETED NA
Artemether/Lumefantrine and Vivax Malaria
NCT01625871 COMPLETED PHASE3